Published in Lab Business Week, September 26th, 2004
"ANSI's actions are evidence that yet another knowledgeable device market leader, in this case with highly relevant FDA [U.S. Food and Drug Administration] experience, has recognized the value of Cyberonics' VNS [vagus nerve stimulation] Therapy franchise, intellectual property, demand creation organization and model, profitable epilepsy business, and depression and other new indications opportunities," commented Robert P....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.